# Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June Canonical URL: https://biopharmsignal.com/news/EDIT/editas-medicine-to-present-in-vivo-hsc-delivery-editing-and-biodistribution-data-05463a27 Ticker: EDIT Company: Editas Medicine Source: Editas Medicine Published: 2025-05-14 13:31 EST ## Summary Preclinical studies achieved therapeutically relevant gene editing levels of the HBG1/2 promoter & favorable biodistribution profile in non-human... ## Article Body Preclinical studies achieved therapeutically relevant gene editing levels of the HBG1/2 promoter & favorable biodistribution profile in non-human primates using a clinically validated editing strategy Data reinforces continued development as a potentially transformative, in vivo approach to treating sickle cell disease and beta thalassemia CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced that new data from a study in non-human primates (NHPs) has been accepted for a poster presentation at the European Hematology Association (EHA) 2025 Congress being held June 12-15, 2025, in Milan, Italy. Key delivery, editing, and biodistribution data from an ongoing study in NHPs will be shared, including: High efficiency HSC delivery of editing cargo. Therapeutically relevant editing levels in the HBG1/2 promoter region exceeding the predicted editing threshold of ≥25% required for therapeutic benefit with a single dose. Favorable biodistribution with Editas’ tLNP, demonstrating significant de-targeting of the liver in contrast to standard LNPs. “We look forward to sharing further data from our in vivo HSC program at EHA, demonstrating therapeutically relevant editing levels and favorable biodistribution in NHPs. These data warrant the further development of Editas’ proprietary HSC-tLNP for editing of the HBG1/2 promoters for the treatment of sickle cell disease and beta thalassemia, and we are encouraged by our significant progress towards the clinic,” said Linda C. Burkly, Ph.D., Executive Vice President and Chief Scientific Officer, Editas Medicine. The presentation details are listed below. Abstracts can be accessed on the EHA website , and the presentation will be posted on the Editas Medicine website during the conference. Poster Presentation Details: Title: Targeted Lipid Nanoparticle Delivery Enables In Vivo HBG1/2 Genome Editing In Non-Human Primates Date/Time: Saturday, June 14, 2025, 6:30 - 7:30 p.m. CEST/ 12:30 – 1:30 p.m. EDT Location: Allianz MiCo, Milano Convention Centre Session: Poster Session 2 About Editas Medicine As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com . ## Recent Company News - 2026-05-28 20:01 EST — [Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference](https://biopharmsignal.com/news/EDIT/editas-medicine-announces-updated-presentation-time-for-upcoming-investor-confer-ef3968d7) — Source: Editas Medicine - 2026-05-26 13:05 EST — [Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering](https://biopharmsignal.com/news/EDIT/editas-medicine-announces-pricing-of-up-to-319-4-million-public-offering-127eec22) — Source: Editas Medicine - 2026-05-26 10:15 EST — [Editas Medicine Announces Proposed Public Offering](https://biopharmsignal.com/news/EDIT/editas-medicine-announces-proposed-public-offering-1685aa73) — Source: Editas Medicine - 2026-05-26 10:01 EST — [Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress](https://biopharmsignal.com/news/EDIT/editas-medicine-presents-edit-401-preclinical-data-demonstrating-robust-reductio-8f1aef48) — Source: Editas Medicine - 2026-05-14 10:01 EST — [Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting](https://biopharmsignal.com/news/EDIT/editas-medicine-reports-new-preclinical-data-demonstrating-progress-of-edit-401--a6308965) — Source: Editas Medicine ## Related News - 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9) - 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627) - 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922) - 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c) - 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)